Surface Oncology
Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights.
Launch date
Employees
Market cap
€59.2m
Enterprise valuation
€17m (Public information from Sep 2023)
Share price
$1.07 SURF
Cambridge Massachusetts (HQ)
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 12.8m | 59.4m | 15.4m | 126m | 2.7m | 30.0m |
| % growth | - | 363 % | (74 %) | 721 % | (98 %) | 1016 % |
| EBITDA | (45.0m) | (7.8m) | (57.4m) | 61.6m | (76.0m) | (61.9m) |
| % EBITDA margin | (351 %) | (13 %) | (373 %) | 49 % | (2829 %) | (206 %) |
| Profit | (45.4m) | (6.6m) | (54.8m) | 59.3m | (78.5m) | (63.6m) |
| % profit margin | (354 %) | (11 %) | (357 %) | 47 % | (2921 %) | (212 %) |
| EV / revenue | - | 0.6x | 3.4x | 3.0x | 61.8x | 5.5x |
| EV / EBITDA | - | -4.4x | -0.9x | 6.1x | -2.2x | -2.7x |
| R&D budget | 47.8m | 52.5m | 52.1m | 41.0m | 53.6m | 67.0m |
| R&D % of revenue | 373 % | 88 % | 339 % | 33 % | 1994 % | 223 % |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$170m | Early VC | ||
$108m Valuation: $432m 33.7x EV/LTM Revenues -9.6x EV/LTM EBITDA | IPO | ||
* | $25.0m | Debt | |
| N/A | $28.9m | Post IPO Equity | |
* | N/A | Acquisition | |
| Total Funding | €186m | ||
Related Content
Recent News about Surface Oncology
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.